Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tianma Xingnao capsule versus Compound Cistanche Yizhi capsule for vascular mild cognitive impairment
ChiCTR2400084132Phase 4Not yet recruiting
- Sponsor
- Yunnan Provincial Hospital of Traditional Chinese Medicine
- Start
- May 2024
- Countries
- 1
01
Overview
Phase 4, randomised trial of Tianma Xingnao Capsule in vascular mild cognitive impairment (VaMCI) (2 arms), sponsored by Yunnan Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: VADAS-cog and CDR-SB. Planned start May 2024; status: not yet recruiting.
02
Drugs
Tianma Xingnao Capsule
03
Conditions
vascular mild cognitive impairment (VaMCI)
Beyond the preview
Go deeper on ChiCTR2400084132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084132.